Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach
Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer - YouTube
Targeted and novel therapy in advanced gastric cancer | Experimental Hematology & Oncology | Full Text
Scenario 1. FLOT, TAS-102, IOs Do They Improve the Lives of Patients With Gastric Cancer? - ppt download
Dihydroartemisinin suppresses proliferation, migration, the Wnt/β‑catenin pathway and EMT via TNKS in gastric cancer Corrigendum in /10.3892/ol.2021.13152
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase
Cancers | Free Full-Text | Recent Developments of Systemic Chemotherapy for Gastric Cancer
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma | Journal of Hematology & Oncology | Full Text
New developments and standard of care in the management of advanced gastric cancer - ScienceDirect
Late-line treatment in metastatic gastric cancer: today and tomorrow | Semantic Scholar
Department of Gastrointestinal Oncology
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm | Nature Reviews Clinical Oncology
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Cancers | Free Full-Text | Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
OncLive - The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience | Gastric Cancer
Novel oral chemotherapeutic holds potential for stomach cancer patients
